Runze Technology delivered a record amount of computing-center capacity in a single quarter, EVE Energy’s fourth-quarter capacity is fully booked, and orders are growing at ProPharma and Asymchem. Demand is moving toward delivery, but equipment billing, capacity deployment and product validation each have their own timing requirements.
Overseas revenue rose to 50.48% of XCMG Machinery’s total in the first half of 2026, making overseas business an important buffer against domestic cycles. Great Wall Securities is optimistic about the structural upgrade brought by electrification and autonomous operation of mining equipment, with complete equipment offerings and overseas order expansion serving as the key links.
Four industry reports show different paths to earnings realization: IDC demand is ahead of revenue, shrinking acetic acid supply is driving a profit recovery, oil tanker spot rates have fallen while time charters remain firm, and faster UHV approvals are raising expectations for tenders.
Wanxiang Qianchao hit its daily upper trading limit and received net institutional buying, with attention focused on precision bearings and screws for robots. Existing automotive-parts processes provide a foundation for entry, but robotics products remain in development and validation; solid-state battery research by an investee company and a proposed overseas acquisition also have distinct conditions for progress.
Its EC chip has received certification from both Intel and AMD and has shipped to customers including Lenovo, Honor and Xiaomi; edge BMC is also in mass production and on sale. The company says these products have higher gross margins than its traditional consumer electronics business, making the product mix key to understanding changes in its operations.
Qiaoyin’s urban-service operations provide an entry point for robot data, but computing-capacity leasing requires capital outlay before revenue arrives. Express delivery volumes, prices and profits are improving together, while China Securities places greater weight on leading companies’ cash generation and their networks’ ability to withstand pressure.
Agibot has set a revenue target of 10 billion yuan for 2027, ten times the 1 billion yuan achieved in 2025. Xiangcai Securities is optimistic about humanoid robots as a practical application of physical AI. In the near term, it is focused on mass production of components; long-term competition will depend on whether model capabilities and real-world operational data can reinforce each other.
Heavy-duty robots are beginning to cover multiple production-line processes, while competition in AI applications is extending to products and commercialization. But market turnover contracted on 26 October, and the numbers of high-turnover robotics and AI companies fell at the same time. Industrial progress and trading activity need to be assessed separately.
Bernstein’s 2026 comparison of hotels in the same locations shows that Marriott commands the strongest room-rate premium, but Hilton and Hyatt are close behind thanks to occupancy. InterContinental Hotels Group lags overall, although its brands are not uniformly weakening. Whether a brand can charge more and fill its rooms matters for owner returns and future expansion.
Bernstein sees the business logic of Instacart joining a larger platform, but is skeptical of a near-term deal: Uber’s financial commitments are tight, while DoorDash is busy with integrations and continues to build its own business. The bank’s acquisition scenario implies 68–74 dollars per share; a deal also depends on buyer interest and regulatory approval.
Bernstein believes Imdelltra’s first-line maintenance data could significantly expand its commercial opportunity; INT strengthens the outlook for postoperative adjuvant treatment, while new lung cancer combinations raise the competitive bar. But the commercial value of efficacy improvements must also be assessed against toxicity, treatment duration and the patient population.
Bernstein raised its Spotify price target from $625 to $725, primarily on the basis that cost controls and an improved content mix could lift 2027 operating profit about 5% above consensus. However, third-quarter profit and cash flow were below consensus, and the cost of renewing record-label agreements is another key variable.
Goldman Sachs expects the Federal Reserve to raise rates at every other meeting, completing the second and final hike of this cycle in December. Markets still price in roughly four hikes in total; the disagreement centers on whether tariff, energy and AI-related price pressures can ease in 2027.
Hisense Home Appliances’ revenue for the third quarter of 2026 was just 4% below Goldman Sachs’ forecast, but net profit was 67% lower. The air-conditioning business faced weak demand, rising copper prices and pressure to cut prices; growth overseas and in refrigerators and washing machines provided support but failed to offset the decline in earnings. Goldman Sachs maintained its Buy rating, with its long-term thesis still dependent on growth in multi-split air-conditioning systems and improved operating efficiency.
A narrower decline in gypsum board sales and continued price increases ended five consecutive quarters of falling revenue, but higher raw material costs and lower production weighed on gross margin. Goldman Sachs cut its earnings forecasts while remaining positive on the scope for recovery through cost optimization and a low valuation.
Riptac showed potential for efficacy and tolerability in prostate cancer patients who had received multiple prior lines of treatment, while Rybrevant offers a new opportunity in head and neck cancer. But Johnson & Johnson already trades at a premium valuation of 21 times expected 2027 earnings per share, limiting its relative upside in JPMorgan's view.
Foreign exchange effects and a higher share of low-margin businesses weighed on earnings, while lower expense ratios provided a partial cushion. Overseas orders grew by more than 50%, supporting Morgan Stanley’s decision to maintain its Overweight rating, but the profit quality of converted orders remains subject to product mix, exchange rates and costs.
The full phase three Pove results are consistent with prior disclosures, and Morgan Stanley remains positive on its combination of efficacy, safety and convenient dosing. The near-term focus shifts to the 30 November regulatory decision and payer coverage after launch; another kidney disease drug, inaxaplin, is due to report kidney function data in early 2027.
Large financing deals and demand for computing capacity continue to support AI expansion, but companies differ markedly in cash flow, contract structures and the conditions for bringing capacity online. Meanwhile, model usage is rising as providers cut prices to win customers.
Intismeran combined with Keytruda significantly improved recurrence-free survival after melanoma surgery, while early pancreatic cancer data provide mechanistic support for expansion into kidney cancer. But the wait for treatment to take effect, tissue sample requirements for manufacturing, and immature overall survival data still constrain the realization of the platform’s value.
